JHU-083 

JHU-083, a proagent of 6-diazo-5-oxo-L-norleucine (DON; HY-108357), is an orally active and selective glutaminase antagonist. JHU-083 blocks glutaminase activity in brain CD11b⁺ cells and experimental cerebral malaria (ECM) resulting in a net decrease of glutamate levels in the animals^[1][2].

JHU-083 (1.82 mg/kg; PO; every other day for 12 days) ameliorates social avoidance behavior and anhedonia-like behavior induced by CSDS^[1].
JHU-083 (1.82 mg/kg, PO) attenuates CSDS-induced increase in glutaminase activity in CD11b+ cells in the prefrontal cortex and hippocampus, but not in the cerebellum. JHU-083 treatment suppresses the CSDS-induced upregulation of IL-1β and TNF-α expression^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

312.36

C₁₄H₂₄N₄O₄

1998725-11-3

Solid

Light yellow to yellow

O=C(OCC)[C@H](CCC(C=[N+]=[N-])=O)NC([C@H](CC(C)C)N)=O

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhu X, et al. JHU-083 selectively blocks glutaminase activity in brain CD11b+ cells and prevents depression-associated behaviors induced by chronic social defeat stress. Neuropsychopharmacology. 2019 Mar;44(4):683-694.  [Content Brief]

  [2]. Riggle BA, et al. MRI demonstrates glutamine antagonist-mediated reversal of cerebral malaria pathology in mice. Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):E12024-E12033.  [Content Brief]